PAREXEL Collaborates with Sanofi to Advance the Use of Wearable Devices in Life Science Industry
June 15 2017 - 8:00AM
Business Wire
Preliminary findings from pilot study validate
use of wearable technologies to collect data and manage clinical
trials more effectively and efficiently
PAREXEL International Corporation (NASDAQ: PRXL), a leading
global biopharmaceutical services organization, today announced a
collaboration with Sanofi to advance the use of wearable devices to
transform the collection of data in clinical trials.
Wearables have the potential to address several challenges
related to clinical trials and improve execution by increasing
patients’ ability to participate, driving patient engagement, and
creating more opportunities for decentralized trial sites. The
PAREXEL-Sanofi collaboration is designed to further explore the
potential of patient sensors and wearable devices to remotely
collect patient data during clinical trials.
The two companies are jointly leveraging their clinical,
scientific, regulatory, logistics and technical expertise, as well
as global footprint, to determine how wearables can optimize study
performance and accelerate drug development. In particular, the
companies are examining how data collected from several wearable
devices can be streamlined into a single, scalable data system to
provide valuable insights.
Currently, PAREXEL and Sanofi are collaborating on a pilot study
using PAREXEL’s recently launched patient sensor solution to
demonstrate the scientific and medical viability of wearables. In
an ongoing single-site study, patient data is being collected
remotely and simultaneously via multiple wearable devices.
Publication of final study results is expected in the near
future.
“We believe the use of wearables to collect data from trial
participants represents a breakthrough in the digital
transformation within the industry,” said Xavier Flinois,
President, PAREXEL Informatics. “Working with Sanofi, we believe we
have a strong opportunity to streamline and automate data
collection from multiple devices, collect high-quality data
remotely and generate meaningful results, all while reducing burden
on patients and sites, as well as lowering costs.”
“Our objective is to demonstrate the relevance of data collected
remotely and the overall feasibility of utilizing wearables in
clinical trials,” said Lionel Bascles, Global Head of Clinical
Sciences and Operations of Sanofi. “Wearables are a core component
of Sanofi’s digital trials strategy, and represent an important
approach to automate patient processes using the latest
technologies to bring new therapies to patients sooner. We are
pleased to be collaborating with PAREXEL and leveraging their
multi-functional expertise in this area. We are committed to
further advancing the potential of this technology.”
PAREXEL’s recently launched patient sensor solution, powered by
the Perceptive MyTrials® Analytics platform, facilitates the remote
collection of study subject data. To deliver this solution, PAREXEL
has partnered with leading technology providers to capture,
securely transmit, store, and monitor data, as well as generate
alerts based on the potentially large volume of time-series data
from sensors.
About PAREXEL InternationalPAREXEL International
Corporation is a leading global biopharmaceutical services company,
providing a broad range of expertise-based clinical research,
consulting, medical communications, and technology solutions and
services to the worldwide pharmaceutical, biotechnology, and
medical device industries. Committed to providing solutions that
expedite time-to-market and peak-market penetration, PAREXEL has
developed significant expertise across the development and
commercialization continuum, from drug development and regulatory
consulting to clinical pharmacology, clinical trials management,
and reimbursement. PAREXEL Informatics provides advanced technology
solutions, including medical imaging, to facilitate the integrated
clinical development and regulatory information management process.
Headquartered near Boston, Massachusetts, PAREXEL has offices in 86
locations in 51 countries around the world, and had approximately
19,370 employees in the third quarter. For more information about
PAREXEL International visit www.PAREXEL.com.
PAREXEL and PAREXEL Informatics are trademarks or registered
trademarks of PAREXEL International Corporation or its affiliates.
All other trademarks are the property of their respective
owners.
This release contains “forward-looking” statements regarding
future results and events. For this purpose, any statements
contained herein that are not statements of historical fact may be
deemed forward-looking statements. Without limiting the foregoing,
the words “believes,” “anticipates,” “plans,” “expects,” “intends,”
“appears,” “estimates,” “projects,” “will,” “would,” “could,”
“should,” “targets,” and similar expressions are also intended to
identify forward-looking statements. The forward-looking statements
in this release involve a number of risks and uncertainties. Such
factors and others are discussed in the section entitled “Risk
Factors” of the Company’s most recent Annual Report on Form 10-K
and subsequent quarterly reports on Form 10-Q filed with the
Securities and Exchange Commission, which “Risk Factors” discussion
is incorporated by reference in this press release. The Company
specifically disclaims any obligation to update these
forward-looking statements in the future. These forward-looking
statements should not be relied upon as representing the Company’s
estimates or views as of any date subsequent to the date of this
press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170615005095/en/
Media:Dana RobieTel.: +1 781-434-4772Email:
Dana.Robie@PAREXEL.comJenny Radloff, PAN CommunicationsTel.: +1
617-502-4300Email: PAREXEL@pancomm.comorInvestors:Ronald
AldridgeTel.: +1 781-434-4753Email: Ron.Aldridge@PAREXEL.com
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Parexel (NASDAQ:PRXL)
Historical Stock Chart
From Apr 2023 to Apr 2024